Ali, D., Callan, N., Ennis , S., Powell, R., McGuire, S., McGregor, G., Weickert, M. O., Miller, Michelle A., Cappuccio, Francesco and Banerjee, P. (2019) The Heart Failure with Preserved Ejection Fraction (HFpEF) Pathophysiology, observational Study (IDENTIFY-HF) : does increased arterial stiffness associate with HFpEF, in addition to ageing and vascular effects of co-morbidities? Rationale and design. BMJ Open, 9 . e027984. doi:10.1136/bmjopen-2018-027984 ISSN 2044-6055.

Preview	PDF WRAP- The-Heart-Failure-with-Preserved-Ejection-Fraction-(HFpEF)-Pathophysiology-observational-Study-(IDENTIFY-HF)-Cappuccio-2019.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons: Attribution-Noncommercial 4.0. Download (689Kb) | Preview
	PDF WRAP-Heart-failure-preserved-ejection-fraction-arterial- stiffness-design-Cappuccio-2018.pdf - Accepted Version Embargoed item. Restricted access to Repository staff only - Requires a PDF viewer. Download (1469Kb)

Request Changes to record.

Abstract

Aims
There has been a paradigm shift proposing that comorbidities are a major contributor towards the heart failure with preserved ejection fraction (HFpEF) syndrome. Furthermore, HFpEF patients have abnormal macro and microvascular function, which may significantly contribute towards altered ventriculo-vascular coupling in these patients. The IDENTIFY-HF study will investigate whether gradually increased arterial stiffness (in addition to ageing) as a result of increasing common comorbidities, such as hypertension and diabetes, is associated with HFpEF.
Methods and analysis:
In our observational study arterial compliance and microvascular function will be assessed in five groups (Groups A to E) of age, sex and BMI matched subjects (age ≥ 70 years in all groups):
Group A; normal healthy volunteers without major comorbidities such as hypertension and diabetes
mellitus (control). Group B; patients with hypertension without diabetes mellitus or heart failure (HF). Group C; patients with hypertension and diabetes mellitus without HF. Group D, patients with HFpEF; Group E; patients with heart failure and reduced ejection fraction (HFrEF) (parallel group). Vascular function and arterial compliance will be assessed using Pulse Wave Velocity, as the primary outcome measure. Further outcome measures include Cutaneous Laser Doppler Flowmetry as a measure of endothelial function, transthoracic echocardiography and exercise tolerance measures. Biomarkers include NT-proBNP, high sensitivity Troponin T, as well as serum galactin-3 as a marker of fibroses.

Item Type:	Journal Article
Alternative Title:
Subjects:	R Medicine > RC Internal medicine R Medicine > RZ Other systems of medicine
Divisions:	Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Mental Health and Wellbeing Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Heart failure , Heart failure -- Treatment, Cardiac arrest, Arteriosclerosis
Journal or Publication Title:	BMJ Open
Publisher:	BMJ
ISSN:	2044-6055
Official Date:	2019
Dates:	Date Event 2019 Published 19 November 2019 Available 24 September 2019 Accepted
Volume:	9
Article Number:	e027984
DOI:	10.1136/bmjopen-2018-027984
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access (Creative Commons)
Date of first compliant deposit:	2 October 2019
Date of first compliant Open Access:	2 October 2019
Related URLs:	Publisher

Request changes or add full text files to a record

Repository staff actions (login required)

View Item

Downloads